尊龙凯时人生就是博·官方(中国)
Home
About Us
About Us
Executive team
Corporate Structure
Brand
Our History
Our Culture
Contact us
News Releases
Business
R&D
Manufacturing
Distribution
Career
Talent concept
Cultivation of talents
Social Responsibility
Responsibility Management
Sustainability Report
CSR News
Investor Relations
Corporate Governance
Governance Structure
The Board
Announcements
Financial Reports
Company Presentations
Stock Price
Analyst Coverage
Investor Relations Contacts
CN
EN
Home
About Us
About Us
Executive team
Corporate Structure
Brand
Our History
Our Culture
Contact us
News Releases
Business
R&D
Manufacturing
Distribution
Career
Talent concept
Cultivation of talents
Social Responsibility
Responsibility Management
Sustainability Report
CSR News
Investor Relations
Corporate Governance
Announcements
Financial Reports
Company Presentations
Stock Price
Analyst Coverage
Investor Relations Contacts
CR Home
中文版
Search
EN
|
Investor Relations
Announcements
Announcements
Investor Relations
Corporate Governance
- Governance Structure
- The Board
Announcements
Financial Reports
Company Presentations
Stock Price
Analyst Coverage
Investor Relations Contacts
Announcements
Home
>
Investor Relations
>
Announcements
28
2025.03
2025/03/28
DISCLOSEABLE TRANSACTION COMPLETION OF THE PROPOSED ACQUISITION OF TASLY PHARMACEUTICALS
27
2025.03
2025/03/27
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
27
2025.03
2025/03/27
FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2024
20
2025.03
2025/03/20
PRINCIPAL FINANCIAL INFORMATION OF JIANGZHONG PHARMACEUTICAL FOR THE YEAR ENDED 31 DECEMBER 2024
20
2025.03
2025/03/20
PRINCIPAL FINANCIAL INFORMATION OF CR DOUBLE-CRANE FOR THE YEAR ENDED 31 DECEMBER 2024
1
2
3
...
126
Next
Back to Top
Contact us
|
site map
|
Disclaimer
|
Privacy Policy
Copyright © China Resources Pharmaceutical Group Limited
京ICP备17049899号 京公网安备11010502056191号
Technical Support:CR DIGITAL
Copyright © China Resources Pharmaceutical Group Limited
京ICP备17049899号
京公网安备11010502056191号
Technical Support:CR DIGITAL
返回到首页
Back to Top